NCT00715676 (2MD-3H-2B) is a Phase 2 clinical trial of DP001 in Osteoporosis, sponsored by Deltanoid Pharmaceuticals.

Who is sponsoring NCT00715676?

NCT00715676 is sponsored by Deltanoid Pharmaceuticals.

What drugs are being tested in NCT00715676?

Interventions in NCT00715676: Placebo, DP001.

What condition does NCT00715676 study?

NCT00715676 studies Osteoporosis.

Is NCT00715676 still recruiting?

NCT00715676 is currently completed. Last updated 7 December 2009.

Are results published for NCT00715676?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2009-12-07 · How we verify

NCT00715676: 2MD-3H-2B

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 2, Double-blind, Randomized, Placebo-Controlled, Daily-dose, Proof-of-concept Study of a Vitamin D Compound in Postmenopausal Women With Osteopenia

Completed Phase 2 Results posted Last updated 7 December 2009

What this trial tests

Phase 2 trial testing Placebo in Osteoporosis in 157 participants. Completed in 1 January 2009.

Timeline

1 March 2007

Primary endpoint
1 December 2008

1 January 2009

Quick facts

Lead sponsor	Deltanoid Pharmaceuticals
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	157
Start date	1 March 2007
Primary completion	1 December 2008
Estimated completion	1 January 2009
Sites	9 locations across United States

Drugs / interventions tested

Placebo
DP001 — full drug profile →

Conditions studied

Osteoporosis — all drugs for Osteoporosis →

Sponsor

Deltanoid Pharmaceuticals — full company profile →

Who can join

Adults 55 to 80, female only, with Osteoporosis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Week 52
Time frame: Baseline and Week 52
Percent change in lumbar spine BMD (relative to baseline) at Week 52

Sponsor's own description

This study will evaluate the effect of a 1-year administration of the vitamin D analog 2-methylene-19-nor-(20S)-1alpha, 25-dihydroxyvitamin D3 (DP001) on bone mineral density (BMD), safety, and tolerability.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical trials registries are underused in the pregnancy and childbirth literature: a systematic review of the top 20 journals.
Yerokhin VV, Carr BK, Sneed G, Vassar M. · · 2016 · cited 6× · PMID 27769265 · DOI 10.1186/s13104-016-2280-3

Verify or expand the search:

Other recruiting trials for Osteoporosis

Currently open trials in the same condition.

NCT07027306 — The Osteoporotic Fracture Classification-based Scoring System for Treatment Decision in Thoracolumbar Osteoporotic Fract · recruiting
NCT07367776 — Patient Education in Osteoporosis (RCT-PATOS) · NA · recruiting
NCT06731608 — OsteoPorotic fracTure preventION System (OPTIONS) Research Study · NA · recruiting
NCT07281586 — Step-down Therapy After Long-term Osteoporosis Treatment · Phase 4 · recruiting
NCT07083557 — Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiome · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00715676 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Deltanoid Pharmaceuticals
Last refreshed: 7 December 2009

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00715676.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing